Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2019
Event: Regulation FD Disclosure regarding the issuance of a press release and corporate presentation containing full-year 2019 revenue and operating expense guidance. The announcement was made in connection with the 37th Annual J.P. Morgan Healthcare Conference.
Key Financial Metrics
The filing text does not provide specific historical financial values (revenue, profit, cash flow, margins, debt, or liquidity) for the current or prior periods. The document serves as a notice that forward-looking guidance for 2019 has been issued in attached Exhibits 99.1 and 99.2, which are furnished but not filed as part of this text.
Material Changes
No material changes to historical financial results are reported in this text. The primary update is the provision of forward-looking guidance for the 2019 fiscal year regarding:
- Full-year revenue for Xtampza ER.
- Full-year revenue for the Nucynta Franchise.
- Total operating expenses for 2019.
Guidance, Outlook, and Risks
Guidance and Outlook: Management provided full-year 2019 guidance for revenue and operating expenses. The outlook includes assumptions regarding market opportunities and key near-term value drivers for the Company's products.
Risks and Contingencies: The filing highlights substantial risks that could cause actual results to differ from guidance, including:
- Regulatory approval maintenance and label restrictions.
- Commercialization success and market acceptance.
- Reimbursement and third-party payor contracts.
- Competition from other products.
- Intellectual property litigation, specifically mentioning Purdue Pharma, L.P. and Teva Pharmaceuticals USA, Inc.
- Supply chain dependencies for active pharmaceutical ingredients.
- Compliance with DEA and other government regulations.
- Loss of key personnel.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation) for the specific numerical values of the 2019 revenue and expense guidance.
- Verify the status of ongoing litigation with Purdue Pharma and Teva Pharmaceuticals.
- Assess the Company's ability to secure adequate supplies of active pharmaceutical ingredients.
- Monitor regulatory developments impacting Xtampza ER and Nucynta Franchise products.
- Confirm the accuracy of expense estimates and capital requirements against actual cash burn rates.